<![CDATA[Hematologic Oncology Update]]>b04197e9-0143-5ab3-a5b2-09e6b0f94cefWed, 01 Apr 2026 20:09:21 +0000Captivate.fmDr. Neil Lovehttps://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.pngHematologic Oncology UpdateDr. Neil LoveDr. Neil LoveFeaturing one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.https://www.researchtopractice.com/browse-tumor-types/hematologic-oncologyfalseepisodichttps://feeds.captivate.fm/hematologic-oncology/nopodcastImmune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>ec30e6b0-3e10-49b5-9f32-5ab1bc03ec6aWed, 01 Apr 2026 15:30:00 -040024:50falsefull25737325CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G RichardsonCELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G RichardsonDr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

]]>Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

]]>065fa467-777f-47b9-aaac-fb88923e15beMon, 23 Mar 2026 14:00:00 -040024:29falsefull25727225Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>4375f172-e05b-4f86-9131-f51374a7ca85Sat, 21 Mar 2026 08:00:00 -040029:16falsefull25717125CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal ShahCD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal ShahDr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

CME information and select publications here.

]]>Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

CME information and select publications here.

]]>216d1ec4-a780-4e64-8fc5-3a7da3cef7d7Fri, 13 Mar 2026 14:00:00 -040001:03:21falsefull25707025Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual MeetingChronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual MeetingProf Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

CME information and select publications here.

]]>Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

CME information and select publications here.

]]>2e83caaf-2599-441e-b28f-edd93f6ada9bWed, 11 Mar 2026 14:00:00 -040047:10falsefull25696925Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>8eceed6f-2a20-4b5e-b242-e0d5b674fee6Mon, 09 Mar 2026 15:30:00 -040019:21falsefull25686825Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>9ea3045b-1386-4d96-8e72-d7e81baa1700Wed, 04 Mar 2026 09:00:00 -040024:25falsefull25676725Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase ModulatorsMultiple Myeloma: Inside the Issue of Cereblon E3 Ligase ModulatorsDr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.

CME information and select publications here.

]]>Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.

CME information and select publications here.

]]>82ec9ebe-d3a4-4183-b673-7124cbe7df83Wed, 18 Feb 2026 14:30:00 -040057:58falsefull25666625Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>dcbf2674-4d30-4272-ba52-8692ac13aca8Fri, 13 Feb 2026 15:30:00 -040017:18falsefull25656525Immune Thrombocytopenia — ASH 2025 ReviewImmune Thrombocytopenia — ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>7fbd8a45-393f-4d54-9acc-84fdd58244c5Fri, 06 Feb 2026 14:30:00 -040001:30:07falsefull25646425Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>664d6119-3fe8-4de0-b2f0-acc94e52c812Tue, 03 Feb 2026 15:30:00 -040023:23falsefull25636325Bispecific Antibodies in the Management of Lymphoma — ASH 2025 ReviewBispecific Antibodies in the Management of Lymphoma — ASH 2025 ReviewProf Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.

CME information and select publications here.

]]>Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.

CME information and select publications here.

]]>2a2c2fe2-09a8-435e-b24d-9c07220c6366Wed, 21 Jan 2026 15:30:00 -040001:01:12falsefull25626225Relapsed/Refractory Multiple Myeloma — ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>10e65826-034d-4c58-acea-95d7cbe6b805Fri, 16 Jan 2026 16:59:00 -040001:01:06falsefull25616125Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionFollicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma.

CME information and select publications here.

]]>Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma.

CME information and select publications here.

]]>dd65539f-482c-43fd-bdf5-a479068209c5Tue, 13 Jan 2026 16:11:00 -040001:56:55falsefull25606025Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionMyelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionProf Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.

CME information and select publications here.

]]>Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.

CME information and select publications here.

]]>f905f06f-57cf-4b18-a0c6-afe412792371Fri, 09 Jan 2026 09:00:00 -040001:57:30falsefull25595925Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionChronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.

CME information and select publications here.

]]>Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.

CME information and select publications here.

]]>2f307335-02d4-4d5a-a7a9-80c8c536515cWed, 07 Jan 2026 15:30:00 -040001:55:47falsefull25585825Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionAcute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.

CME information and select publications here.

]]>Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.

CME information and select publications here.

]]>a3d94a63-b9be-4954-be20-9c7b49e879ccSat, 03 Jan 2026 09:00:00 -040001:57:33falsefull25575725Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkChronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. 

CME information and select publications here.

]]>f72e3caf-1dca-4616-9249-7d8d6c9073bbFri, 12 Dec 2025 15:00:00 -040051:19falsefull25565625CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by PatientsCAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by PatientsDr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   

CME information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   

CME information and select publications here.

]]>f4aefd1c-ff3d-43a0-a133-7d2501c8dd40Thu, 11 Dec 2025 15:30:00 -040058:30falsefull25555525Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew LunningToxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew LunningDr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   

CME information and select publications here.

]]>Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   

CME information and select publications here.

]]>be263928-35f6-4dba-8210-69fc45f096f5Thu, 04 Dec 2025 15:00:00 -040052:03falsefull25545425Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell TherapyPatient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell TherapyDr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. 

Educational information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. 

Educational information and select publications here.

]]>ea5b87be-3136-4fc4-9413-3c8a1e7e7104Sat, 15 Nov 2025 08:00:00 -040059:42falsefull25535325Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDiffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. 

CME information and select publications here.

]]>Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. 

CME information and select publications here.

]]>da2eb223-bf2b-4ec9-87a8-1d040b0a4bd3Thu, 13 Nov 2025 14:30:00 -040001:00:13falsefull25525225Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHAAcute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHADr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  

CME information and select publications here.

]]>Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  

CME information and select publications here.

]]>a362511e-8465-4810-9e29-acfe398d3125Thu, 23 Oct 2025 15:00:00 -040054:59falsefull25515125Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease ManagementNon-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease ManagementDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. 

CME information and select publications here.

]]>04d3a015-6b53-4e20-90f1-d38012fc1f53Sat, 18 Oct 2025 09:00:00 -040057:59falsefull25505025Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingFollicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingDr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  

CE information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  

CE information and select publications here.

]]>b801e877-6404-44d1-bdd1-c8e3a87380a3Fri, 10 Oct 2025 19:34:00 -040059:34falsefull25494925Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin InhibitorsAcute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin InhibitorsDr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. 

CME information and select publications here.

]]>Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. 

CME information and select publications here.

]]>87898e1e-b346-49ac-98d8-fd669b23b834Thu, 09 Oct 2025 16:00:00 -040058:47falsefull25484825Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingRelapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingProf Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  

CE information and select publications here.

]]>Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  

CE information and select publications here.

]]>f17e9409-7dfd-41e2-abdc-229579cf2e34Fri, 03 Oct 2025 09:00:00 -040058:29falsefull25474725Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell TherapyOncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell TherapyDr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>d2d6454f-b48a-4cbe-a3f8-f2644056e4a9Fri, 19 Sep 2025 17:04:00 -040053:08falsefull25464625Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementDr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>887d8dc4-acec-4927-b18e-0f812a482b08Tue, 16 Sep 2025 15:00:00 -040054:23falsefull25454525Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementProf Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>5531a2d9-5180-44cb-8c8e-b786adb9b0a5Mon, 15 Sep 2025 15:30:00 -040057:47falsefull25444425Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise GleasonOncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise GleasonMs Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>bdfe3ea6-a732-4bd5-8ef5-7a6a7b3f21c8Sat, 06 Sep 2025 10:00:00 -040054:17falsefull25434325Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier LeleuOncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier LeleuProf Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. 

NCPD information and select publications here.

]]>Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. 

NCPD information and select publications here.

]]>5e689fc8-c12a-4c81-8a26-15aa0af7bbcbFri, 05 Sep 2025 15:00:00 -040053:08falsefull25424225Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsRelapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsDr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>2c7592fe-e5f1-4ff7-8668-4a169090cc6dFri, 29 Aug 2025 10:00:00 -040059:21falsefull25414125Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaMultiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. 

Educational and faculty information here.

]]>For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. 

Educational and faculty information here.

]]>46cbb1c5-54bd-43ad-bad3-b06617fca1abFri, 15 Aug 2025 12:00:00 -040001:02:11falsefull25404025Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 MutationsAcute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 MutationsDr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. 

CME information and select publications here.

]]>Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. 

CME information and select publications here.

]]>0c23c2a4-7073-496a-86f4-c26212f760c3Tue, 12 Aug 2025 11:00:00 -040043:01falsefull25393925Multiple Myeloma — Optimizing the Selection of First-Line TherapyMultiple Myeloma — Optimizing the Selection of First-Line TherapyProf Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. 

CME information and select publications here.

]]>Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. 

CME information and select publications here.

]]>988097fd-e041-4bdf-8a52-648658842b38Thu, 07 Aug 2025 13:00:00 -040057:11falsefull25383825Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual MeetingChronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. 

CME information and select publications here.

]]>Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. 

CME information and select publications here.

]]>0fcd8059-866b-406d-ac50-ff9331651f77Tue, 22 Jul 2025 11:00:00 -040001:00:43falsefull25373725Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingMultiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingDr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. 

CME information and select publications here.

]]>Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. 

CME information and select publications here.

]]>26dd8c3f-774a-4389-9318-215baf292618Fri, 18 Jul 2025 14:00:00 -040058:41falsefull25363625For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS CongressDr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events.   

NCPD information and select publications here.

]]>Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events.   

NCPD information and select publications here.

]]>b00b74c8-856a-4e3e-bdf2-408455742c36Mon, 14 Jul 2025 09:00:00 -040001:30:22falsefull25353525Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingNon-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>86afe982-49d4-4ea1-b2a0-cf4fa4ead709Thu, 10 Jul 2025 09:00:00 -040001:59:42falsefull25343425For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS CongressDr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. 

NCPD information and select publications here.

]]>Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. 

NCPD information and select publications here.

]]>8631a8cd-ee8e-4713-9528-93973aa21627Sat, 05 Jul 2025 09:00:00 -040001:26:53falsefull25333325For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS CongressDr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. 

NCPD information and select publications here.

]]>Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. 

NCPD information and select publications here.

]]>b51f6879-c6f1-4ad0-9ba6-49498f7ebeb5Sat, 28 Jun 2025 09:00:00 -040001:26:22falsefull25323225IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesIDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesDr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>e2f18a58-78c2-4c7c-9a96-8154e696bd45Tue, 24 Jun 2025 12:00:00 -040054:07falsefull25313125Multiple Myeloma — Year in Review Series on Relevant New Datasets and AdvancesMultiple Myeloma — Year in Review Series on Relevant New Datasets and AdvancesProf Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. 

CME information and select publications here.

]]>Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. 

CME information and select publications here.

]]>ffe8974b-479e-4923-94f3-754ebf15b830Wed, 18 Jun 2025 08:00:00 -040059:09falsefull25303025Myelofibrosis — Year in Review Series on Relevant New Datasets and AdvancesMyelofibrosis — Year in Review Series on Relevant New Datasets and AdvancesProfessor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. 

CME information and select publications here.

]]>Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. 

CME information and select publications here.

]]>83c9d611-7bde-459e-a072-7bd9605cd32bWed, 11 Jun 2025 15:00:00 -040059:18falsefull25292925Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and AdvancesNon-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and AdvancesDr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>25975428-5534-4636-8d34-9769e8ead2edThu, 05 Jun 2025 14:00:00 -040059:08falsefull25282825Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology SummitSystemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  

CME information and select publications here.

]]>43545253-3e8a-4cee-9b09-8a8fec8cc4cfMon, 02 Jun 2025 09:00:00 -040047:55falsefull25272725Multiple Myeloma — Fourth Annual National General Medical Oncology SummitMultiple Myeloma — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of multiple myeloma.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of multiple myeloma.  

CME information and select publications here.

]]>76a0af0f-770a-4624-8e76-bb98b55b6a57Sat, 31 May 2025 09:00:00 -040050:41falsefull25262625Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingMultiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>b2721017-e5ac-4841-9c7d-838876e7c850Thu, 29 May 2025 10:00:00 -040050:50falsefull25252525Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingChronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>4bd304ae-ee51-446e-b5fa-a1d925cec975Sun, 25 May 2025 09:00:00 -040048:22falsefull25242425Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel TherapiesRelapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel TherapiesDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>412f6c50-9444-4064-86af-b938360c8d8fFri, 23 May 2025 12:00:00 -040042:34falsefull25232325Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific AntibodiesNon-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific AntibodiesDr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas.   

CME information and select publications here.

]]>Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas.   

CME information and select publications here.

]]>e4118bd2-0295-4fab-8dc5-5007a9d044d7Tue, 20 May 2025 14:00:00 -040049:54falsefull25222225Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell TherapyRelapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell TherapyDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>af519947-3e70-429f-8948-b012f98ead12Fri, 16 May 2025 16:00:00 -040037:08falsefull25212125Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology SummitNon-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  

CME information and select publications here.

]]>35d209ee-a1c7-4df6-ae02-9be11f6c88ccMon, 12 May 2025 16:00:00 -040050:03falsefull25202025Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingNon-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. 

CME information and select publications here.

]]>Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. 

CME information and select publications here.

]]>62b3be8a-5085-4fc2-92b0-f13c03b160e5Sat, 10 May 2025 09:00:00 -040052:36falsefull25191925Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and AdvancesChronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and AdvancesDr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. 

CME information and select publications here.

]]>a253c046-d882-4a5e-b2da-d16748686df9Sat, 03 May 2025 09:00:00 -040059:14falsefull25181825Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management StrategiesImmune Thrombocytopenia — A Roundtable Discussion on Current and Future Management StrategiesDr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. 

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. 

CME information and select publications here.

]]>d90b4a03-4e17-47cf-b540-3a27e8517fa0Mon, 28 Apr 2025 16:36:00 -040001:56:57falsefull25171725Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific AntibodiesRelapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific AntibodiesDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>fdce2bdf-db65-4d24-b48a-96467fb6ebe1Tue, 22 Apr 2025 10:00:00 -040040:11falsefull25161625Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. 

NCPD information and select publications here.

]]>Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. 

NCPD information and select publications here.

]]>0b89d8a3-9d83-4880-a39c-baccd75cd98eFri, 18 Apr 2025 09:00:00 -040058:21falsefull25151525Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingMyelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. 

CME information and select publications here.

]]>Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. 

CME information and select publications here.

]]>45fee4ec-c26b-40eb-859d-c8855954fe37Tue, 15 Apr 2025 06:00:00 -040043:18falsefull25141425Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology SummitChronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of chronic lymphocytic leukemia.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of chronic lymphocytic leukemia.  

CME information and select publications here.

]]>bbea62af-c350-4c81-a925-9a20def8bfe4Sat, 12 Apr 2025 09:00:00 -040050:12falsefull25131325Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent ConferencesChronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent ConferencesDr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>645d9bc2-e0db-40fb-b2ea-75e206a30b52Fri, 04 Apr 2025 09:00:00 -040058:13falsefull25121225For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A RichardsFor Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A RichardsDr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.

NCPD information and select publications here.

]]>Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.

NCPD information and select publications here.

]]>72b3e3dd-9007-4f9a-bbae-aa8c671cc5d1Mon, 24 Mar 2025 14:00:00 -040001:05:16falsefull25111125Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. 

NCPD information and select publications here.

]]>Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. 

NCPD information and select publications here.

]]>52ae964e-25a1-48ff-b2f0-e8b5a9994521Tue, 18 Mar 2025 06:00:00 -040001:05:59falsefull25101025Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management StrategiesRelapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management StrategiesProf Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.

CME information and select publications here.

]]>Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.

CME information and select publications here.

]]>f35c4526-ad09-4bb7-ad15-074b6e65f8f9Tue, 25 Feb 2025 13:00:00 -040002:33:01falsefull259925Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell TherapyMultiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell TherapyDr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. 

CME information and select publications here.

]]>Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. 

CME information and select publications here.

]]>f6e6d9dc-2313-4730-bf80-1612c05ba1b6Wed, 19 Feb 2025 15:00:00 -040046:45falsefull258825Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar UsmaniMultiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar UsmaniDr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. 

CME information and select publications here.

]]>Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. 

CME information and select publications here.

]]>c1c8c524-637e-487f-936e-2cf61fb2c3b7Tue, 11 Feb 2025 15:00:00 -040046:45falsefull257725Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor SeriesChronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor SeriesDr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here

]]>Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here

]]>b0f61e98-c60a-4a3e-9465-f430f1edc0e7Thu, 30 Jan 2025 14:00:00 -040059:28falsefull256625Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaData + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaDr Joshua Brody from The Tisch Cancer Institute in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from The University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

CME information and select publications here.

]]>Dr Joshua Brody from The Tisch Cancer Institute in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from The University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

CME information and select publications here.

]]>14d676df-e289-4b11-ac51-5d3dc5446fb9Thu, 23 Jan 2025 12:19:00 -040059:32falsefull255525CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesCAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.

]]>Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.

]]>A93E6FEE-A4F0-460A-B1BE-02519BB5C67FThu, 16 Jan 2025 12:00:00 -040002:00:29falsefull254425Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesMyelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

]]>Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

]]>1931A8A4-EA31-4717-A82E-F0070BE71F6BTue, 14 Jan 2025 12:00:00 -040001:59:15falsefull253325Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesChronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesProf Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.

]]>Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.

]]>F55BA107-AE12-4A47-BE47-F3DD7919E403Thu, 09 Jan 2025 12:07:00 -040001:27:00falsefull252225Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesAcute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.

]]>Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.

]]>D64C74BE-08BE-4907-A633-040E45A4660BTue, 07 Jan 2025 12:23:00 -040001:58:50falsefull251125Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesMultiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesProf Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma.

]]>Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma.

]]>F4578F45-6D07-4C78-ACD9-A42E82A29DDAFri, 20 Dec 2024 16:23:00 -040001:57:11falsefull24282824Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma.Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesChronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

]]>Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

]]>DEE2B986-CBD6-4F6D-A203-EEBC380AA6F0Thu, 19 Dec 2024 11:59:00 -040001:57:07falsefull24272724Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.Cases from the Community: Integrating New Research Findings into Current Practice — MyelofibrosisCases from the Community: Integrating New Research Findings into Current Practice — MyelofibrosisDr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.

]]>Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.

]]>4A0F771B-4A19-4191-BC15-A36A3EF3EF52Tue, 17 Dec 2024 11:18:00 -040051:43falsefull24262624Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic SyndromesCases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic SyndromesDr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.

]]>Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.

]]>7878BB38-BCF3-4B01-A9F1-AB0704595484Fri, 13 Dec 2024 12:10:00 -040051:45falsefull24252524Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal HemoglobinuriaPractical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal HemoglobinuriaDr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria.

]]>Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria.

]]>7E5C38A2-D96C-4A4A-8E51-3942F1DAAEB9Wed, 04 Dec 2024 09:23:00 -040001:46:37falsefull24242424Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria.Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple MyelomaData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple MyelomaSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma.

]]>8AB03CCD-E35B-4BB9-8F9B-4059C964996BTue, 26 Nov 2024 12:29:00 -040052:45falsefull24232324Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma.Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part SeriesDr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.

]]>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.

]]>1337D5E5-6CE2-4C58-8099-605C970DE777Fri, 22 Nov 2024 17:01:00 -040058:36falsefull24222224Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

]]>94425AB7-1DBF-40DD-8201-E8EF874E46F2Wed, 20 Nov 2024 12:36:00 -040056:11falsefull24212124Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with LymphomaWhat Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with LymphomaDr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.

]]>Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.

]]>11B0F509-77DF-4747-8681-441997D88CCBFri, 08 Nov 2024 12:46:00 -040056:15falsefull24202024Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell LymphomaPractical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell LymphomaDr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

]]>Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

]]>A28FF0D3-9141-4AFB-B400-60F728F021F5Wed, 30 Oct 2024 12:27:00 -040057:58falsefull24191924Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.Practical Perspectives: Current Management of Chronic Myeloid LeukemiaPractical Perspectives: Current Management of Chronic Myeloid LeukemiaDrs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.

]]>Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.

]]>EFB269D8-9F10-4DA0-816F-62B764B2CD63Thu, 24 Oct 2024 12:58:00 -040001:49:21falsefull24181824Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.Oncology Today with Dr Neil Love: Peripheral T-Cell LymphomaOncology Today with Dr Neil Love: Peripheral T-Cell LymphomaDr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.

]]>Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.

]]>D8E527CB-D936-4773-9900-C5880FD43703Thu, 17 Oct 2024 12:12:00 -040046:33falsefull24171724Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part SeriesDr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.

]]>Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.

]]>110450FB-B253-490C-8212-317E76A451BDThu, 10 Oct 2024 11:40:00 -040058:58falsefull24161624Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple MyelomaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple MyelomaDr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.

]]>Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.

]]>312D9505-B894-4E29-B894-1C0D989153C4Mon, 12 Aug 2024 12:15:00 -040001:02:04falsefull24151524Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of LymphomaRTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of LymphomaDr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.

]]>Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.

]]>4A934721-74E1-4ADF-A69D-70F12FB4CBC9Fri, 12 Jul 2024 12:19:00 -040001:00:49falsefull24141424Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in MyelofibrosisYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in MyelofibrosisDr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.

]]>Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.

]]>8E3ABB89-088E-4082-895D-08B70C7E17AATue, 02 Jul 2024 12:11:00 -040001:00:07falsefull24131324Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major ConferencesOncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major ConferencesDr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.

]]>Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.

]]>991F2FB4-1059-4198-A10B-D14F359B7811Wed, 29 May 2024 13:20:00 -040001:16:46falsefull24121224Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaOncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaDr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

]]>Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

]]>EA91A2AD-9344-4EBD-8860-DD66C8136468Tue, 28 May 2024 12:17:00 -040033:54falsefull24111124Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple MyelomaOncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple MyelomaDr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.

]]>Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.

]]>8967108E-1DA2-4B2B-B39C-808ED7AC7867Fri, 24 May 2024 09:31:00 -040042:09falsefull24101024Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid LeukemiaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid LeukemiaDrs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.

]]>Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.

]]>0DE318CC-0E7D-4131-BEC6-73A003CE546ETue, 14 May 2024 11:53:00 -040001:02:07falsefull249924Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part SeriesDr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.

]]>Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.

]]>DBF805FC-461B-4750-A595-6D4DE75AE619Thu, 02 May 2024 12:13:00 -040001:00:54falsefull248824Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal HemoglobinuriaStriving for Consensus: Current and Future Management of Paroxysmal Nocturnal HemoglobinuriaDr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.

]]>Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.

]]>4BD13EC0-F023-4723-9A9B-56F2730BD325Fri, 26 Apr 2024 11:03:00 -040001:37:17falsefull247724Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major ConferencesOncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major ConferencesDr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.

]]>Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.

]]>4E9F1FF3-1874-4EA2-A6F2-7FC2FA7848AEWed, 24 Apr 2024 11:15:00 -040001:04:36falsefull246624Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major ConferencesOncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major ConferencesDr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.

]]>Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.

]]>79556FA6-7F3D-4920-B1CE-B35AE027DBB1Fri, 12 Apr 2024 14:00:00 -040001:35:12falsefull245524Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in LymphomaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in LymphomaDr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.

]]>Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.

]]>63CCF67C-66C8-4110-83C0-BCF0864806F4Wed, 27 Mar 2024 09:12:00 -040001:00:13falsefull244424Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part SeriesDr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.

]]>Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.

]]>29B3FC0F-FC69-4C84-A525-0E99C76AF029Fri, 08 Mar 2024 09:45:00 -040001:00:13falsefull243324Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaDr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.

]]>Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.

]]>5FEB7F8C-95C9-4248-BE15-BD272F0F8C62Tue, 27 Feb 2024 09:55:00 -040058:02falsefull242224Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part SeriesDr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

]]>Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

]]>E2469E69-600B-4B6A-8C53-5C7BA8A543E0Wed, 17 Jan 2024 05:34:00 -040001:00:25falsefull241124Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part SeriesDr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.

]]>Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.

]]>3C9ACB36-9FE9-46D4-A356-DA271EB29D80Fri, 10 Nov 2023 14:36:00 -040001:01:30falsefull23313123Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part SeriesDr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

]]>Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

]]>DF529E81-71A1-4703-94BE-A8714927B92FFri, 20 Oct 2023 15:43:00 -040001:01:44falsefull23303023Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell LymphomaWhat Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell LymphomaDr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

]]>Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

]]>A335942B-1F4D-4F04-8314-20FA38760893Thu, 19 Oct 2023 11:23:00 -040001:01:33falsefull23292923Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology ConferencesOncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology ConferencesDr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.

]]>Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.

]]>B36C7F9A-25DD-427F-B82E-37BF2BC9CF0BWed, 18 Oct 2023 11:40:00 -040001:19:48falsefull23282823Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew MatasarOncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew MatasarDr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

]]>Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

]]>56F103AC-218F-4FC3-B488-45663D669EBCThu, 12 Oct 2023 11:31:00 -040046:28falsefull23272723Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaWhat Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaProf Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.

]]>Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.

]]>53C48E06-6590-4045-8A99-36FA0FCAE0BDMon, 09 Oct 2023 10:02:00 -040047:30falsefull23262623Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell NeoplasmOncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell NeoplasmDr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.

]]>Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.

]]>422A728D-C178-48BA-BDC8-0049794753E4Thu, 05 Oct 2023 10:51:00 -040033:52falsefull23252523Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple MyelomaOncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple MyelomaDr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma.

]]>Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma.

]]>1ECB8B34-4A74-4EAC-B5DB-75A6CED640DFThu, 28 Sep 2023 10:37:00 -040039:10falsefull23242423Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma.What Clinicians Want to Know About Toxicity Considerations Associated with BTK InhibitorsWhat Clinicians Want to Know About Toxicity Considerations Associated with BTK InhibitorsDr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

]]>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

]]>40C52402-7321-45AF-B3FB-59327C4198BCFri, 22 Sep 2023 15:29:00 -040001:02:44falsefull23232323Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin LymphomaInside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin LymphomaDr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

]]>Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

]]>76E9CB41-934F-40CC-A7DB-1E1976941826Thu, 14 Sep 2023 10:14:00 -040001:00:42falsefull23222223Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell LymphomaOncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell LymphomaFeaturing a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

]]>Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

]]>B620BEF7-3F37-40F8-A9E9-3697996FD496Thu, 31 Aug 2023 11:37:00 -040042:34falsefull23212123Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesDr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

]]>Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

]]>5DDDF00C-1FBC-4132-949A-4698DDB588CDWed, 30 Aug 2023 11:14:00 -040001:01:53falsefull23202023Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology ConferencesOncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology ConferencesDr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.

]]>Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.

]]>D87DD1F8-EC48-4658-8024-E0DB28D6B37ATue, 29 Aug 2023 11:09:00 -040036:06falsefull23191923Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity ManagementInside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity ManagementDr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

]]>Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

]]>2A5E6153-9D53-4D55-A229-8BB6EE01B033Wed, 23 Aug 2023 11:07:00 -040001:00:50falsefull23181823Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.Oncology Today with Dr Neil Love: Special Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic LeukemiaOncology Today with Dr Neil Love: Special Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic LeukemiaDr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia

]]>Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia

]]>62029F83-2751-49ED-BE0F-B04D2C654A9BFri, 18 Aug 2023 12:37:00 -040001:09:31falsefull23171723Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemiaInside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic SyndromesInside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic SyndromesFeaturing perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love.

]]>Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love.

]]>1319987D-940F-42C0-B87C-689A5ACE94C1Wed, 02 Aug 2023 10:20:00 -040001:03:15falsefull23161623Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Immune Thrombocytopenia EditionOncology Today with Dr Neil Love: Immune Thrombocytopenia EditionDr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.

]]>Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.

]]>87F6BFCA-9A07-4CF8-8B73-E94483EDDB0DMon, 31 Jul 2023 10:51:00 -040029:27falsefull23151523Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.Oncology Today with Dr Neil Love: Management of Paroxysmal Nocturnal HemoglobinuriaOncology Today with Dr Neil Love: Management of Paroxysmal Nocturnal HemoglobinuriaFeaturing a discussion on the biology and treatment of paroxysmal nocturnal hemoglobinuria with Dr Carlos de Castro, moderated by Dr Neil Love.

]]>Featuring a discussion on the biology and treatment of paroxysmal nocturnal hemoglobinuria with Dr Carlos de Castro, moderated by Dr Neil Love.

]]>CD412931-FD15-43D6-BA45-37488174A76EWed, 26 Jul 2023 11:15:00 -040042:57falsefull23141423Featuring a discussion on the biology and treatment of paroxysmal nocturnal hemoglobinuria with Dr Carlos de Castro, moderated by Dr Neil Love.Meet The Professor: The Current and Future Management of Non-Hodgkin LymphomaMeet The Professor: The Current and Future Management of Non-Hodgkin LymphomaFeaturing a discussion on the management of non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.

]]>6223ED49-E185-4366-AAD7-14FA96095A1DMon, 10 Jul 2023 10:41:00 -040001:01:23falsefull23131323Featuring a discussion on the management of non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part SeriesFeaturing a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.

]]>42CE9F68-3474-4D0A-AD46-21BE16CD160BFri, 16 Jun 2023 10:38:00 -040001:01:32falsefull23121223Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic SyndromesYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic SyndromesProceedings from our Year in Review webinar on the management of acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on the management of acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, moderated by Dr Neil Love.

]]>00E19C72-7091-4A6F-A93A-0E09D14F4FC0Fri, 21 Apr 2023 12:07:00 -040001:01:55falsefull23111123Proceedings from our Year in Review webinar on the management of acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma EditionOncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma EditionFeaturing a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.

]]>Featuring a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.

]]>C6142962-2D38-4F87-9149-D0C8FE427D58Wed, 19 Apr 2023 10:50:00 -040001:14:49falsefull23101023Featuring a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia EditionOncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia EditionFeaturing a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.

]]>Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.

]]>A1B863A4-C635-4BD2-A0C0-1B09BB81AA9AWed, 12 Apr 2023 10:14:00 -040001:19:48falsefull239923Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.Recent Advances and Future Directions in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Danielle Brander and Craig Moskowitz (Proceedings from a Symposium in Partnership with NCOA and SCOS)Recent Advances and Future Directions in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Danielle Brander and Craig Moskowitz (Proceedings from a Symposium in Partnership with NCOA and SCOS)Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>22D04ED9-48C2-474F-8EE6-03290236E543Fri, 17 Mar 2023 12:34:00 -040059:32falsefull238823Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.Oncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual MeetingOncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual MeetingFeaturing a discussion on lymphoma studies presented at ASH 2022, with Dr Matthew Lunning, moderated by Dr Neil Love.

]]>Featuring a discussion on lymphoma studies presented at ASH 2022, with Dr Matthew Lunning, moderated by Dr Neil Love.

]]>BA0F4F0F-42DD-4AC6-A0BA-FF255E87E215Thu, 02 Mar 2023 12:46:00 -040001:28:19falsefull237723Featuring a discussion on lymphoma studies presented at ASH 2022, with Dr Matthew Lunning, moderated by Dr Neil Love.Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK InhibitorsInside the Issue — Optimizing the Management of Adverse Events Associated with BTK InhibitorsProceedings from a webinar on optimizing the management of adverse events associated with BTK inhibitors with Drs Farrukh Awan and Kerry Rogers, moderated by Dr Neil Love.

]]>Proceedings from a webinar on optimizing the management of adverse events associated with BTK inhibitors with Drs Farrukh Awan and Kerry Rogers, moderated by Dr Neil Love.

]]>9A428F41-91B4-4740-9759-A306B957CEB8Thu, 23 Feb 2023 09:54:00 -040001:03:39falsefull236623Proceedings from a webinar on optimizing the management of adverse events associated with BTK inhibitors with Drs Farrukh Awan and Kerry Rogers, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin LymphomasYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin LymphomasProceedings from our Year in Review webinar on the management of lymphomas. Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on the management of lymphomas. Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, moderated by Dr Neil Love.

]]>48C1B1B8-507F-415B-B35D-F19E8AA28C60Fri, 17 Feb 2023 17:57:00 -040001:03:44falsefull235523Proceedings from our Year in Review webinar on the management of lymphomas. Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part SeriesFeaturing a discussion on the treatment of multiple myeloma with Dr Noopur Raje, moderated by Dr Neil Love.

]]>Featuring a discussion on the treatment of multiple myeloma with Dr Noopur Raje, moderated by Dr Neil Love.

]]>AD5532A6-F9DC-420C-A5FC-C3AF0B59003FTue, 14 Feb 2023 10:27:00 -040001:01:05falsefull234423Featuring a discussion on the treatment of multiple myeloma with Dr Noopur Raje, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual MeetingOncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting53CEFDD4-86E2-4FFB-940E-498F238A7071Thu, 09 Feb 2023 09:41:22 -040001:19:13falsefullFeaturing a discussion on newly presented data with myelofibrosis, polycythemia vera and essential thrombocythemia with Dr Srdan Verstovsek, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell LymphomaOncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell LymphomaCBC17048-5922-4336-B846-62553E29D7EAMon, 06 Feb 2023 11:01:59 -040043:37falsefullFeaturing a discussion on recent data with targeted therapies for the treatment of diffuse large B-cell lymphoma with Dr Gilles Salles, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual MeetingOncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual MeetingC648DC00-7D74-40A3-8D0A-D2B9EBAC8736Thu, 02 Feb 2023 11:02:46 -040001:10:12falsefullFeaturing a discussion on newly presented data in acute myeloid leukemia and myelodysplastic syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple MyelomaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma90DFE701-BBD7-47A1-BD60-56025BFAACF0Wed, 01 Feb 2023 10:11:50 -040001:04:50falsefullProceedings from our Year in Review webinar on the management of multiple myeloma. Featuring perspectives from Drs Joseph Mikhael and Ajay Nooka, moderated by Dr Neil Love. Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaProceedings from our Year in Review webinar on the management of chronic lymphocytic leukemia. Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on the management of chronic lymphocytic leukemia. Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, moderated by Dr Neil Love.

]]>9D864C41-C720-4DC7-B1CC-ED19932FC566Fri, 20 Jan 2023 11:11:00 -040001:02:40falsefull233323Proceedings from our Year in Review webinar on the management of chronic lymphocytic leukemia. Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 3 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Multiple Myeloma — Part 3 of a 4-Part SeriesFeaturing a discussion on the treatment of multiple myeloma with Dr Shaji Kumar, moderated by Dr Neil Love.

]]>Featuring a discussion on the treatment of multiple myeloma with Dr Shaji Kumar, moderated by Dr Neil Love.

]]>70F7924B-9BBF-4D55-8BD2-FA4BACB81786Thu, 19 Jan 2023 09:21:00 -040001:01:29falsefull232223Featuring a discussion on the treatment of multiple myeloma with Dr Shaji Kumar, moderated by Dr Neil Love.What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid LeukemiaWhat Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid LeukemiaFeaturing perspectives from Drs Courtney DiNardo and Mark Levis, moderated by Dr Neil Love.

]]>Featuring perspectives from Drs Courtney DiNardo and Mark Levis, moderated by Dr Neil Love.

]]>D22376E3-BDAC-41D1-A899-11F68D897EDDFri, 13 Jan 2023 11:00:00 -040001:00:22falsefull231123Featuring perspectives from Drs Courtney DiNardo and Mark Levis, moderated by Dr Neil Love.